• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Oct31
Nanobiotix SA Enters into Royalty Monetization Agreement with Healthcare Royalty
07:01
Oct24
Nanobiotix transfers head and neck cancer trial control to Johnson & Johnson
06:00
Oct4
Nanobiotix SA ADR Reports Significant H1 2025 Revenue Growth, Narrowed Net Loss
03:56
Oct1
Nanobiotix SA released FY2025 Semi-Annual Earnings on September 30 (EST), actual revenue USD 30.01 M (forecast USD 8.154 M), actual EPS USD -0.1278 (forecast USD -0.4448)
03:00
Nanobiotix SA released FY2025 Q2 earnings on September 30 (EST), actual revenue USD 15.59 M, actual EPS USD -0.0664
03:00
Nanobiotix SA released FY2025 Q1 earnings on September 30 (EST), actual revenue USD 14.42 M, actual EPS USD -0.0614
03:00

Schedules & Filings

Schedules
Filings
Sep30
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 15.59 M, Net Income -3.151 M, EPS -0.0664

Apr2
Earning Release(EST)

FY2024 Q4 Earning Release (USD) Revenue -8.57 M, Net Income -24.06 M, EPS -0.5088

Sep18
Earning Release(EST)

FY2024 Q2 Earning Release (USD) Revenue 4.975 M, Net Income -11.72 M, EPS -0.2485

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
PCSA
6.866
+128.50%
+3.825
ATPC
0.1484
+64.89%
+0.058
YCBD
2.320
+62.24%
+0.895
VYNE
0.6025
+49.62%
+0.200
ISPO
4.190
+47.54%
+1.350
MGRT
7.250
+35.51%
+1.900
GVH
3.800
+28.81%
+0.850
MDLN
37.163
+28.15%
+8.070
ANDG
20.410
+27.56%
+4.350
DBVT
22.550
+25.42%
+4.570
View More